ReviewMaterials (Basel, Switzerland)2026
Advances in TCP-Modified PMMA Bone Cements: Relating Microstructure to Mechanical, Biological and Functional Performance-Systematic Review.
Review in Materials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The main objective of this systematic review was to synthesise current knowledge on tricalcium phosphate (TCP) as a functional modifier of poly(methyl methacrylate) (PMMA)-based bone cements, relating the microstructure of PMMA/TCP composites to their mechanical, biological and functional (handling) performance. Web of Science, Scopus and PubMed were searched for 2010-2025. Studies reporting primary quantitative data on PMMA cements specifically modified with TCP were eligible. Over one hundred records were screened by two independent reviewers, yielding 15 studies appraised qualitatively and combined by narrative synthesis. The evidence links polymerisation of the PMMA matrix, calcium and phosphate ion release from TCP, apatite-layer precipitation, and cell-mediated TCP resorption coupled to bone remodelling. TCP, especially β-TCP or biphasic calcium phosphate systems, can balance mechanical stability with bioactivity: moderate β-TCP contents (of the order of 10 wt% for solid cements under quasi-static compression) preserve clinically acceptable properties while enhancing osteoconductivity, though this limit falls for porous, α-TCP-containing and fatigue-loaded formulations. Porosity, TCP amount, crystalline form and particle size are the governing microstructural variables. The evidence is limited, dominated by in vitro and short-term static tests, with heterogeneous formulations and no controlled clinical data, so benefits should be interpreted qualitatively rather than as firm quantitative relationships. The review was not registered; this research received no external funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.